As of 3:59pm ET
| -0.0168 / -0.77%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 4.66, with a high estimate of 10.00 and a low estimate of 2.62. The median estimate represents a +114.52% increase from the last price of 2.17.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.